AI's ability to rapidly analyze massive datasets is revolutionizing drug discovery, cutting research timelines from around 6 years to as little as 2-4 years, leading to significant cost savings and faster delivery of life-saving treatments, as evidenced by the accelerated development of COVID-19 mRNA vaccines.
Huawei's Watch 5 boasts a unique fingertip sensor that enables advanced health tracking features like EKGs, blood oxygen, and arterial stiffness detection, but the company's claim of an 'exact purple' color option appears questionable based on promotional images.
Meta's AI research division unveils groundbreaking datasets and models, including Open Molecules 2025 for molecular discovery, and insights into how language representations develop in the brain, mirroring large language models, potentially revolutionizing science and language processing.
Anthropic, a pioneering AI company, has teamed up with Menlo Ventures to launch the $100 million Anthology Fund, aimed at fueling startups leveraging Anthropic's cutting-edge AI technology across diverse sectors like healthcare, education, and consumer solutions, while fostering innovation and societal benefits.
Groundbreaking AI technology is revolutionizing mammography screening by accurately triaging low-risk cases, enabling radiologists to focus on high-risk and complex cases, potentially reducing costs by up to 30% through efficient collaboration between AI and human experts.
MBZUAI unveils the Institute of Digital Public Health, harnessing AI foundation models and a data-driven approach to drive innovation across computational biology, precision medicine, infectious disease monitoring, and the UAE Genome Atlas for transformative public health solutions.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
Researchers have developed a groundbreaking method combining test-time augmentation and conformal prediction, enhancing AI model reliability by up to 30% for critical tasks like medical diagnosis, enabling more accurate and efficient decision-making in high-stakes scenarios.
In a groundbreaking development, researchers have harnessed the power of AI and machine learning to analyze patient data, enabling the prediction of Alzheimer's disease up to 7 years before symptoms manifest, with high cholesterol and osteoporosis emerging as key predictors.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.